Important Deadline Approaches for Investors in Rocket Pharmaceuticals Class Action Lawsuit
On June 13, 2025, Levi & Korsinsky, LLP, a well-regarded law firm, has notified investors of Rocket Pharmaceuticals, Inc. (traded under NASDAQ: RCKT) regarding a crucial opportunity to join a class action lawsuit. This lawsuit is aimed at seeking compensation for investors who suffered losses due to alleged securities fraud that took place between February 27, 2025, and May 26, 2025.
The crux of the lawsuit involves claims that Rocket Pharmaceuticals made optimistic public statements to its investors while simultaneously concealing significant adverse facts regarding the safety and clinical trial protocols of their RP-A501 product. Specifically, the complaint alleges that Rocket was aware of Serious Adverse Events (SAEs) connected to the trial, including participant fatalities, yet failed to disclose this information. The company reportedly amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, further intensifying the claims of misleading conduct.
The timeline escalated on May 27, 2025, when Rocket Pharmaceuticals announced a clinical hold imposed by the FDA on the RP-A501 Phase 2 pivotal study. This decision came after one patient experienced a Serious Adverse Event, leading to their death, while partaking in the trial concurrent with protocol amendments that had not been disclosed to investors. Notably, Rocket acknowledged that the decision to modify the protocol occurred “several months earlier” but did not inform anyone until after the tragedy unfolded. Consequently, the aftermath saw the company’s stock plummeting by about 37% in a single trading day, dropping from $6.27 to $2.33 per share.
Investors who bought Rocket’s securities during the specified timeframe and incurred losses now have until August 11, 2025, to request appointment as lead plaintiffs in the lawsuit. Participation in the lawsuit provides a way for affected shareholders to potentially recover some of their losses without requiring any upfront fees. Levi & Korsinsky reassures investors that, should they qualify as class members, they can seek compensation without incurring any expenses.
The firm has built a solid reputation over the past two decades, successfully recovering hundreds of millions in compensation for aggrieved investors involved in high-stakes cases. Their seasoned team excels in navigating complex securities litigation, consistently ranking among the top litigation firms in the United States according to ISS Securities Class Action Services.
For Rocket Pharmaceuticals investors who believe they have been affected by these recent developments, this class action lawsuit offers a potential pathway toward justice and recovery. If you wish to learn more or participate, do not hesitate to reach out to Levi & Korsinsky, LLP. You can contact attorney Joseph E. Levi via email or at the provided telephone number. Overall, taking action promptly is pivotal, as the deadline approaches soon.
Levi & Korsinsky’s commitment to their clients, characterized by extensive expertise and a robust support structure comprising over 70 professionals, positions them effectively to advocate for investors’ rights, emphasizing a proactive approach when facing potential securities fraud.
Contact Information:
Address:
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Background of the Class Action
The crux of the lawsuit involves claims that Rocket Pharmaceuticals made optimistic public statements to its investors while simultaneously concealing significant adverse facts regarding the safety and clinical trial protocols of their RP-A501 product. Specifically, the complaint alleges that Rocket was aware of Serious Adverse Events (SAEs) connected to the trial, including participant fatalities, yet failed to disclose this information. The company reportedly amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, further intensifying the claims of misleading conduct.
The timeline escalated on May 27, 2025, when Rocket Pharmaceuticals announced a clinical hold imposed by the FDA on the RP-A501 Phase 2 pivotal study. This decision came after one patient experienced a Serious Adverse Event, leading to their death, while partaking in the trial concurrent with protocol amendments that had not been disclosed to investors. Notably, Rocket acknowledged that the decision to modify the protocol occurred “several months earlier” but did not inform anyone until after the tragedy unfolded. Consequently, the aftermath saw the company’s stock plummeting by about 37% in a single trading day, dropping from $6.27 to $2.33 per share.
Action Required for Affected Investors
Investors who bought Rocket’s securities during the specified timeframe and incurred losses now have until August 11, 2025, to request appointment as lead plaintiffs in the lawsuit. Participation in the lawsuit provides a way for affected shareholders to potentially recover some of their losses without requiring any upfront fees. Levi & Korsinsky reassures investors that, should they qualify as class members, they can seek compensation without incurring any expenses.
The firm has built a solid reputation over the past two decades, successfully recovering hundreds of millions in compensation for aggrieved investors involved in high-stakes cases. Their seasoned team excels in navigating complex securities litigation, consistently ranking among the top litigation firms in the United States according to ISS Securities Class Action Services.
Conclusion
For Rocket Pharmaceuticals investors who believe they have been affected by these recent developments, this class action lawsuit offers a potential pathway toward justice and recovery. If you wish to learn more or participate, do not hesitate to reach out to Levi & Korsinsky, LLP. You can contact attorney Joseph E. Levi via email or at the provided telephone number. Overall, taking action promptly is pivotal, as the deadline approaches soon.
Levi & Korsinsky’s commitment to their clients, characterized by extensive expertise and a robust support structure comprising over 70 professionals, positions them effectively to advocate for investors’ rights, emphasizing a proactive approach when facing potential securities fraud.
Contact Information:
- - Joseph E. Levi, Esq.
- - Email: [email protected]
- - Phone: (212) 363-7500
Address:
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.